Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin in the Treatment of SARS-CoV-2
NCT04853199Phase 1Completed
- Sponsor
- Hôpital Universitaire Sahloul
- Start
- Jun 2021
- Primary completion
- Jul 2021
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Quercetin group with Placebo Group (2 arms). Primary endpoints: Mortality rate at 30 days, Need for ICU admission at 30 days and 1 more. Started Jun 2021; status: completed.
02
Drugs
quercetin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04853199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853199.